Fact CheckerSign in

NCT05901727Active, not recruiting

DSD Models at Malawi Sentinel Sites (SENTINEL 2-Malawi)

Outcomes of Differentiated Models of Service Delivery for HIV Treatment at Sentinel Sites in Malawi (Sentinel-Malawi)

Source: ClinicalTrials.gov · Last updated 27 Jan 2026

Brief summary (registry, in English)

To achieve global goals for the treatment of HIV, many countries are piloting and scaling up differentiated service delivery models (DSD). A handful of efforts have been formally described and evaluated in the literature; many others are being implemented formally or informally under routine care, without a research or evaluation goal. For most countries however, the investigators have little evidence on progress and challenges at the facility level-the number of patients actually participating in DSD models, health outcomes and non-health outcomes, effects on service delivery capacity and clinic efficiency and operations, and costs to providers and patients. AMBIT is a set of data synthesis, data collection, and data analysis activities aimed at generating information for near- and long-term decision making and creating an approach and platform for ongoing evaluation of differentiated models of HIV treatment delivery. The first AMBIT protocol, "Gathering Records to Evaluate Antiretroviral Treatment" (GREAT, Malawi NHRC 2376), collects and analyzes comprehensive patient medical record data, allowing us to assess the effect of DSD models on patients' clinical outcomes and to evaluate uptake of DSD models at scale. The Sentinel-Malawi study, the second AMBIT protocol, is examining the effect of DSD models on patient and provider satisfaction, service delivery capacity and quality, costs to patients, and other outcomes for which data are not routinely collected in patient-level medical records. The first round of Sentinel-Malawi was conducted in 2021. The investigators are now amending the protocol to allow up to two additional annual rounds of data collection, in 2022-2023. The investigators collected clinic aggregate data, conducted surveys of patients and providers, and observed operations at a selected set of 12 Malawian healthcare facilities and their affiliated DSD models in Round 1. Round 2 and 3 will collect the same types of data at 12 facilities in Malawi and will expand the study's research questions to include differentiated models of HIV testing and linkage to care. Results are expected to inform Malawian policy makers and other local and international stakeholders on the actual implications of DSD models for patients, health system operations, and healthcare budgets.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
15520 (estimated)
First submitted
5 Jun 2023
Start date
1 Jun 2021
Primary completion date
14 Dec 2024
Lead sponsor
Boston University
Diseases
HIV
NCT number
NCT05901727

What you commit to

  • Study type: Observational
  • Planned participants: 15520
  • From 1 Jun 2021 to the primary completion date, 14 Dec 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • ● None.
  • ● None.
  • Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant
  • Not physically, mentally, or emotionally able to participate in the study, in the opinion of the investigators or study staff.
  • Unwilling to take the time required to complete the questionnaire on the day of consent.
  • Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant
  • Not physically, mentally, or emotionally able to participate in the study, in the opinion of the investigators or study staff.
  • Unwilling to take the time required to complete the questionnaire on the day of consent.

Who the study is looking for

  • Patient-facing or patient-supporting service provider at the study site (patient-supporting providers include data clerks, pharmacists, etc.)
  • Directly or indirectly involved in the site's implementation of ART and DSD models
  • Employed in current role at the study site for at least six months
  • Provides written informed consent to participate
  • Direct or indirect service provider at the study site (indirect providers include supervisors, technical advisors, etc.)
  • Directly or indirectly involved in the site's implementation of ART and DSD models
  • Employed in current role at the study site for at least six months
  • Provides written informed consent to participate.
  • Living with HIV and on ART for at least six months at the study site
  • ≥ 16 years old (16 and older considered adult for research purposes in Malawi)
  • Enrolled in a specified model of care (including conventional care) up to the target number of participants for that model and have received at least one medication refill under this model
  • Provide written informed consent to participate.
  • Undergoing HIV testing at the study site or other testing site within the catchment area
  • ≥ 16 years old (16 and older considered adult for research purposes in Malawi)
  • Provide written informed consent to participate.

Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CHAI-Malawi
Coordinator of this site? Confirm its status
LilongweMalawiUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.